<DOC>
	<DOCNO>NCT02348177</DOCNO>
	<brief_summary>The purpose study determine lopinavir level blood HIV TB infect child ( 3-15kg ) give lopinavir/ritonavir 1:1 ratio rifampicin contain TB regimen safety .</brief_summary>
	<brief_title>Pharmacokinetics Lopinavir/Ritonavir Superboosting Infants Young Children Co-infected With HIV TB</brief_title>
	<detailed_description>This multicentre , open label , non-randomized , prospective , noninferiority study compare pharmacokinetics lopinavir administer superboosting ( LPV/r 1:1 ) concurrent RIF treatment standard boosting ( LPV/r 4:1 ) without concurrent RIF treatment , assess safety , tolerance , virological effect superboosting HIV-TB co-infected infant child weigh &gt; 3 kg ≤15 kg . LPV/r administer liquid 80/20 mg/mL formulation ( 4:1 standard boost ratio ) . During anti-TB treatment , additional RTV liquid formulation provide deliver 1:1 superboosting ratio LPV RTV . Actual dose antiretrovirals anti-TB drug base South African ( SA ) weight band dose recommendation provide per site standard care .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Documentation confirm diagnosis HIV1 infection follow SA clinical guideline Weight &gt; 3kg ≤15 kg enrolment &gt; 42 week gestational age On LPV/rbased therapy start LPV/rbased antiretroviral combination therapy 2 NRTIs [ ABC+3TC AZT+3TC d4T+3TC ] Clinical diagnosis TB require RIFbased therapy Parent legal guardian able willing provide write informed consent able attend study visit . For neonate , less 42 week gestation 14 day old Concomitant/chronic treatment potent enzymeinducing/inhibiting drug study treatment . See Appendix E ( minor inducers/inhibitors drug use part management condition allow eg . Steroids ) Anticipation start antiTB treatment duration longer 9 month Any condition/finding , investigator 's opinion , would compromise child 's participation study eg . alanine transferase ( ALT ) 10 time upper limit normal ( ULN ) , chronic renal , hepatic gastrointestinal disease malabsorption . Children known malignancy contraindication take LPV/r Treatment experimental drug indication within 30 day prior study entry ; participation another study may approve study team .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Human immunideficiency virus</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>superboosting</keyword>
	<keyword>lopinavir/ritonavir 1:1</keyword>
	<keyword>Pediatric TB/HIV co-infection</keyword>
</DOC>